Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Non-Current Assets (2019 - 2026)

Opus Genetics has reported Non-Current Assets over the past 13 years, most recently at $186000.0 for Q1 2026.

  • Quarterly Non-Current Assets fell 22.18% to $186000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $823000.0 through Mar 2026, up 67.62% year-over-year, with the annual reading at $199000.0 for FY2025, 21.03% down from the prior year.
  • Non-Current Assets was $186000.0 for Q1 2026 at Opus Genetics, down from $199000.0 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $252000.0 in Q4 2024 and troughed at $3000.0 in Q3 2023.
  • The 5-year median for Non-Current Assets is $9000.0 (2022), against an average of $104307.7.
  • Year-over-year, Non-Current Assets plummeted 57.14% in 2023 and then fell 21.03% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $6000.0 in 2022, then crashed by 50.0% to $3000.0 in 2023, then skyrocketed by 8300.0% to $252000.0 in 2024, then fell by 21.03% to $199000.0 in 2025, then decreased by 6.53% to $186000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRD's Non-Current Assets are $186000.0 (Q1 2026), $199000.0 (Q4 2025), and $212000.0 (Q3 2025).